NORCANTHARIDINE TREATMENT INHIBITS TRIPLE NEGATIVE BREAST CANCER PROGRESSION

ARIZA BAREÑO, LIZETH AIXA; SCHEY, ALDANA MAGALÍ; BRITEZ NEIRA, DIEGO JAVIER; URTREGER, ALEJANDRO JORGE

Mar del Plata, Buenos Aires

Congreso; REUNIÓN DE SOCIEDADES DE BIOCIENCIAS 2023; 2023

Sociedad Argentina de Investigación Clínica

Triple negative breast cancer (TNBC) is an aggressive subtype characterized by the absence of estrogen and progesterone receptors, as well as HER2 overexpression. Due the lack of specific targeted therapies, there is a clear imperative to explore new therapeutic strategies. Norcantharidin (NCTD), a promising natural compound, has previously shown antitumor effects against lung and liver malignancies. However, its impact on TNBC remains unknown. Therefore, our work aimed to investigated the potential therapeutic implications of NCTD in TNBC. Using human (HS578T) and murine (4T1) TNBC cell lines, we observed a significant antiproliferative effect of NCTD with IC50 values of 56 μM and 35 μM respectively, as determined by the MTS assay. Moreover, fluorescence microscopy (acridine orange/BrEt staining), flow cytometry (Annexin V/IP staining) and Western blot analysis (modulation of cleaved caspase 3 and Parp levels) revealed apoptosis induction. Additionally, NCTD reduced adhesive and migratory capacities in both cell lines, along with a notable decrease in MMP-9 secreted activity (p